CY1124814T1 - Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμα - Google Patents
Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμαInfo
- Publication number
- CY1124814T1 CY1124814T1 CY20211101062T CY211101062T CY1124814T1 CY 1124814 T1 CY1124814 T1 CY 1124814T1 CY 20211101062 T CY20211101062 T CY 20211101062T CY 211101062 T CY211101062 T CY 211101062T CY 1124814 T1 CY1124814 T1 CY 1124814T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pi3k
- tertitagent
- hydroxy groups
- imidazole derivatives
- derivatives substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574057P | 2017-10-18 | 2017-10-18 | |
| US201762608897P | 2017-12-21 | 2017-12-21 | |
| US201862727316P | 2018-09-05 | 2018-09-05 | |
| PCT/US2018/056311 WO2019079469A1 (en) | 2017-10-18 | 2018-10-17 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124814T1 true CY1124814T1 (el) | 2022-11-25 |
Family
ID=64110207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101062T CY1124814T1 (el) | 2017-10-18 | 2021-12-03 | Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμα |
Country Status (35)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020007593A2 (pt) * | 2017-10-18 | 2020-09-24 | Incyte Corporation | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama |
| KR102814342B1 (ko) | 2017-12-19 | 2025-05-29 | 터닝 포인트 테라퓨틱스, 인크. | 질병 치료용 대환식 화합물 |
| PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| MA53097A (fr) | 2018-07-05 | 2021-05-12 | Incyte Corp | Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| EP3980010A4 (en) | 2019-06-04 | 2023-06-07 | Arcus Biosciences, Inc. | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS |
| JP2021165246A (ja) * | 2020-04-08 | 2021-10-14 | 国立大学法人 名古屋工業大学 | ペンタフルオロエチル基含有アルコール類の製造方法、有機半導体材料および酵素活性阻害剤の製造中間体化合物 |
| CN115286521B (zh) * | 2022-07-11 | 2023-11-03 | 上海医药集团(本溪)北方药业有限公司 | 一种盐酸左沙丁胺醇的合成方法 |
| CN120677157A (zh) * | 2024-01-18 | 2025-09-19 | 海创药业股份有限公司 | 一种制备雄激素受体靶向降解化合物及其盐的方法 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| WO2003024967A2 (en) | 2001-09-19 | 2003-03-27 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| EP1441737B1 (en) | 2001-10-30 | 2006-08-09 | Novartis AG | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| WO2004078943A2 (en) | 2003-03-04 | 2004-09-16 | California Institute Of Technology | Alternative heterocycles for dna recognition |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| KR100872204B1 (ko) * | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
| WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물 |
| AU2006278504B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| JP2009507032A (ja) | 2005-09-02 | 2009-02-19 | アボット・ラボラトリーズ | 新規なイミダゾ系複素環 |
| DE602007004618D1 (de) | 2006-06-22 | 2010-03-18 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren |
| CA2681813A1 (en) | 2007-03-27 | 2009-01-08 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| CN101910152B (zh) | 2007-11-16 | 2014-08-06 | 因塞特公司 | 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺 |
| EP2234487A4 (en) | 2007-12-19 | 2011-09-07 | Scripps Research Inst | ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE |
| AU2009232276B2 (en) | 2008-01-15 | 2013-10-24 | Kineta Four Llc | Antiviral drugs for treatment of arenavirus infection |
| WO2009108546A1 (en) | 2008-02-26 | 2009-09-03 | Merck & Co., Inc. | Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia |
| MX2010010012A (es) | 2008-03-11 | 2010-10-20 | Incyte Corp | Derivados de azetidina y ciclobutano como inhibidores de jak. |
| AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
| US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
| WO2010061903A1 (ja) | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2010135014A1 (en) | 2009-02-27 | 2010-11-25 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CN102428087B (zh) * | 2009-04-16 | 2015-06-17 | 卡洛斯三世国家癌症研究中心基金会 | 用作激酶抑制剂的咪唑并吡嗪类化合物 |
| TW201100429A (en) | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| HRP20140754T2 (hr) | 2009-06-29 | 2015-07-17 | Incyte Corporation | Pirimidinoni kao inhibitori pi3k |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AR079529A1 (es) | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| PH12015502575A1 (en) | 2010-03-10 | 2017-04-24 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EP2552208A4 (en) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2011149874A2 (en) | 2010-05-26 | 2011-12-01 | Schering Corporation | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| PH12013500723A1 (en) | 2010-10-13 | 2017-08-23 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| CA2818545C (en) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| PH12013501099A1 (en) | 2010-11-30 | 2013-07-08 | Takeda Pharmaceuticals Co | Bicyclic compound |
| WO2012087881A1 (en) | 2010-12-20 | 2012-06-28 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| LT3196202T (lt) | 2011-09-02 | 2019-07-10 | Incyte Holdings Corporation | Heterociklilaminai, kaip pi3k slopikliai |
| WO2013104610A1 (en) * | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines as akt kinase inhibitors |
| US9212169B2 (en) | 2012-03-01 | 2015-12-15 | Hyogo College Of Medicine | Benzimidazole derivative and use thereof |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| BR112014029501B1 (pt) | 2012-05-31 | 2020-05-19 | Sumitomo Chemical Co | composto heterocíclico fundido, seu uso, agente de controle de pragas e método para o controle de pragas |
| BR112015000675B1 (pt) | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| WO2014149207A2 (en) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Benzimidazole-based insecticidal compositions and related methods |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| US9394254B2 (en) | 2013-05-08 | 2016-07-19 | The University of Denver and Regis University | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase |
| UA117830C2 (uk) | 2013-05-17 | 2018-10-10 | Інсайт Корпорейшн | Похідні біпіразолу як інгібітори jak |
| JP6503336B2 (ja) | 2013-07-17 | 2019-04-17 | 大塚製薬株式会社 | シアノトリアゾール化合物 |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ763326A (en) | 2014-04-08 | 2023-04-28 | Incyte Holdings Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| EP2930048A1 (en) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Head up display projecting visual information onto a screen |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| AU2015317904A1 (en) | 2014-09-16 | 2017-04-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2807785T3 (es) * | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| US10023576B2 (en) * | 2014-10-22 | 2018-07-17 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| WO2016106624A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| JP2018515524A (ja) | 2015-05-12 | 2018-06-14 | カリーラ ファーマシューティカルズ，インク． | 二環式化合物 |
| AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| EP3400221B1 (en) | 2016-01-05 | 2020-08-26 | Incyte Corporation | Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors |
| TW201803871A (zh) * | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| RU2019108464A (ru) | 2016-08-26 | 2020-09-28 | Мицубиси Танабе Фарма Корпорейшн | Бициклическое азотсодержащее гетероциклическое соединение |
| US20200000713A1 (en) | 2017-01-20 | 2020-01-02 | Massachusetts Institute Of Technology | Injectable polymer micro-depots for controlled local drug delivery |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| EP3658539B1 (en) | 2017-07-24 | 2024-02-21 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| SG11202003225YA (en) | 2017-10-18 | 2020-05-28 | Epizyme Inc | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof |
| BR112020007593A2 (pt) | 2017-10-18 | 2020-09-24 | Incyte Corporation | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama |
| KR102814342B1 (ko) | 2017-12-19 | 2025-05-29 | 터닝 포인트 테라퓨틱스, 인크. | 질병 치료용 대환식 화합물 |
| EP3728199B1 (en) | 2017-12-21 | 2025-05-14 | Basf Se | Pesticidal compounds |
| PH12020550786A1 (en) | 2017-12-21 | 2021-04-12 | Boehringer Ingelheim Int | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
-
2018
- 2018-10-17 BR BR112020007593-0A patent/BR112020007593A2/pt unknown
- 2018-10-17 CA CA3084589A patent/CA3084589A1/en active Pending
- 2018-10-17 GE GEAP201816013A patent/GEP20257716B/en unknown
- 2018-10-17 MX MX2020003862A patent/MX2020003862A/es unknown
- 2018-10-17 SG SG11202003428VA patent/SG11202003428VA/en unknown
- 2018-10-17 WO PCT/US2018/056311 patent/WO2019079469A1/en not_active Ceased
- 2018-10-17 TW TW112118992A patent/TWI834560B/zh active
- 2018-10-17 US US16/163,341 patent/US10738057B2/en active Active
- 2018-10-17 SM SM20210656T patent/SMT202100656T1/it unknown
- 2018-10-17 HU HUE18797408A patent/HUE056615T2/hu unknown
- 2018-10-17 JO JOP/2020/0086A patent/JOP20200086A1/ar unknown
- 2018-10-17 AU AU2018350980A patent/AU2018350980C1/en active Active
- 2018-10-17 CR CR20210442A patent/CR20210442A/es unknown
- 2018-10-17 MA MA50398A patent/MA50398B1/fr unknown
- 2018-10-17 HR HRP20211827TT patent/HRP20211827T1/hr unknown
- 2018-10-17 IL IL295978A patent/IL295978B1/en unknown
- 2018-10-17 UA UAA202002916A patent/UA128085C2/uk unknown
- 2018-10-17 SI SI201830506T patent/SI3697789T1/sl unknown
- 2018-10-17 KR KR1020247033485A patent/KR20240152947A/ko active Pending
- 2018-10-17 MD MDE20200857T patent/MD3697789T2/ro unknown
- 2018-10-17 RS RS20211581A patent/RS62818B1/sr unknown
- 2018-10-17 TW TW107136622A patent/TWI803525B/zh active
- 2018-10-17 IL IL295978A patent/IL295978B2/en unknown
- 2018-10-17 LT LTEPPCT/US2018/056311T patent/LT3697789T/lt unknown
- 2018-10-17 EP EP18797408.4A patent/EP3697789B1/en active Active
- 2018-10-17 CR CR20200214A patent/CR20200214A/es unknown
- 2018-10-17 KR KR1020207014142A patent/KR102717072B1/ko active Active
- 2018-10-17 PT PT187974084T patent/PT3697789T/pt unknown
- 2018-10-17 CN CN202311732701.XA patent/CN118063470A/zh active Pending
- 2018-10-17 GE GEAP201815327A patent/GEP20237483B/en unknown
- 2018-10-17 CN CN201880081276.3A patent/CN111542526B/zh active Active
- 2018-10-17 EP EP21196484.6A patent/EP4006034A1/en active Pending
- 2018-10-17 ES ES18797408T patent/ES2902390T3/es active Active
- 2018-10-17 JP JP2020521911A patent/JP7244504B2/ja active Active
- 2018-10-17 PE PE2020000403A patent/PE20210169A1/es unknown
- 2018-10-17 PL PL18797408T patent/PL3697789T3/pl unknown
-
2020
- 2020-04-16 SA SA520411783A patent/SA520411783B1/ar unknown
- 2020-04-16 IL IL273983A patent/IL273983B2/en unknown
- 2020-04-17 PH PH12020550442A patent/PH12020550442A1/en unknown
- 2020-04-17 CL CL2020001047A patent/CL2020001047A1/es unknown
- 2020-05-04 EC ECSENADI202024651A patent/ECSP20024651A/es unknown
- 2020-06-26 US US16/913,488 patent/US11225486B2/en active Active
-
2021
- 2021-11-30 US US17/537,674 patent/US11926630B2/en active Active
- 2021-12-03 CY CY20211101062T patent/CY1124814T1/el unknown
-
2022
- 2022-01-26 ZA ZA2022/01220A patent/ZA202201220B/en unknown
-
2023
- 2023-03-09 JP JP2023036727A patent/JP7541594B2/ja active Active
- 2023-05-17 AU AU2023203088A patent/AU2023203088B2/en active Active
-
2024
- 2024-02-01 US US18/430,528 patent/US20240228498A1/en active Pending
- 2024-12-23 AU AU2024287193A patent/AU2024287193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125245T1 (el) | Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα | |
| CY1124814T1 (el) | Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμα | |
| CY1125169T1 (el) | ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1122886T1 (el) | Αναστολεις βρωμοεπικρατειων | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
| CY1123663T1 (el) | Πυριμιδινονες ως αναστολεις τελεστη χια | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1123906T1 (el) | Αναστολεις απομεθυλασης ιστονης | |
| CY1122550T1 (el) | Αρυλικες, ετεροαρυλικες και ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση των διαταραχων που διαμεσολαβουνται απο το συμπληρωμα | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| CY1123983T1 (el) | Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου | |
| CY1121195T1 (el) | Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1 | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CL2017002606A1 (es) | Inhibidor de bromodominio | |
| MX392673B (es) | Derivados de pirazol como inhibidores de malt1 | |
| CY1117204T1 (el) | ΕΝΩΣΕΙΣ ΤΡΙΑΖΟΛΟΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ mPGES-1 | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| CY1120534T1 (el) | Μακροκυκλικοι αναστολεις παραγοντα χια συμπυκνωμενοι με ετεροκυκλους | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 |